Jump to content

AstraZeneca share price rebounds following FY21 results update


MongiIG

Recommended Posts

In this article we review the AstraZeneca results and how the share price has reacted to the news.

bg_astrazeneca_336609093.jpgSource: Bloomberg
 Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Thursday 10 February 2022 

AstraZeneca's fourth quarter (Q4) and full-year (FY) results have seen the group’s share price bucking the short-term sector trend as of late as it gains on the news.

A summary of the results is as follows:

  • Total revenue for the year increased by 41% to $37,417 million including COVID-19 vaccine revenues
  • Total Revenue for the year, excluding vaccines, increased 26% to $33,436m
  • Reported earnings per share (EPS) of $0.08 in FY21 vs $2.44 in FY20
  • Core EPS of $5.29 in FY21 vs $4.02 in FY20

FY22 outlook

AstraZeneca has provided the following in terms of the new financial year's outlook:

  • The majority of vaccine revenue in 2022 is expected to come from initial contracts
  • The Gross Profit Margin from the COVID-19 medicines is expected to be lower than the company average
  • Core Operating Expenses are expected to increase by a low-to-mid teens percentage, driven in substantial part by the full-year integration of Alexion expenses
  • Emerging Markets Total Revenue, including China, is expected to grow mid-single digits in FY 2022
  • China Total Revenue is expected to decline by a mid-single digit percentage in FY 2022, primarily due to continued NRDL and VBP programme impacting various medicines
  • The company remains confident in the longer term outlook for Emerging Markets, driven by a large market opportunity, broader patient access and an increased mix of new medicines

Comments on results

Double-digit growth across all of the group’s major jurisdictions, combined with the Alexion acquisition, has seen strong revenue growth for the group.

The reported drop in EPS (97%) reflects items related to the acquisition of Alexion, amortisation of intangibles, as well as impairments and restructuring charges.

The Core EPS figure, which omits the one-off items, highlights growth of around 32% in the group's primary operations.

While future earnings growth from COVID-19 products is expected to slow, the group is perhaps less reliant on these products than its peers, Pfizer and Moderna as a proportion of income and future growth.

Astrazeneca – technical analysis

AZ%201002.pngSource: IG charts

 

The share price of AstraZeneca has formed a sharp bullish price reversal near the 8120 level and from oversold territory. The reversal suggests 8860 and 8960 respectively as upside resistance targets from the move.

Traders looking to go long might consider using a close below 8120 as a stop-loss indication for the trade, although will need to assess whether the risk-to-reward is a favourable enough opportunity for the position.

Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • General Statistics

    • Total Topics
      21,632
    • Total Posts
      91,899
    • Total Members
      41,911
    • Most Online
      7,522
      10/06/21 10:53

    Newest Member
    PBEE
    Joined 25/03/23 10:02
  • Posts

    • Charting the Markets: 24 March The FTSE 100, DAX 40 and Nasdaq 100 slide on renewed banking woes while EUR/USD, EUR/GBP and GBP/USD drop as the US dollar, gold appreciate due to flight-to-quality flows. Crude oil and copper tumble on recession fears.  Axel Rudolph FSTA | Senior Financial Analyst, London | Publication date: Friday 24 March 2023         This is here for you to catch up but if you have any ideas on markets or events you want us to relay to the TV team we’re more than happy to.  
    • Market Breakdown | WTI Oil, EURUSD, GBPNZD, EURAUDHere are the updates & outlook for multiple instruments in my watchlist.1️⃣ WTI Oil daily time frame️The market is trading in a long term bearish trend .After the last sharp bearish movement, the market is steadily recovering.Ahead, I see a major horizontal supply area.Probabilities are high, that the next bearish wave will initiate from there.2️⃣ EURUSD daily time frameAfter a breakout of a solid daily resistance, the market is preparing for its retest.Watch carefully the underlined zone and look for buying opportunities from there.3️⃣ EURAUD weekly time frameThe pair is currently approaching a weekly horizontal resistance cluster.Taking into consideration, that the pair is quite overbought, probabilities will be high to see a pullback from that4️⃣ GBPNZD daily time frameThe pair is currently retesting a broken neckline of an ascending triangle . As we discussed earlier, the trend line of a triangle and its neckline compose a contracting buy zone now.Chances will be high that the next bullish wave will initiate quite soon.For Additional confirmation use: Divergence Indicators
    • #CHFJPY: Classic Bearish Setup 🇨🇭🇯🇵   🔻CHFJPY has nicely respected a confluence zone based on a horizontal 4H resistance and a 0.5 retracement of the last bearish impulse.   The price formed a double top pattern on that and broke its neckline.   Probabilities will be high that the pair will drop lower soon. Goals: 141.172 / 140.363  
×
×
  • Create New...